Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc.
May 16 2017 - 1:31PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Intra-Cellular
Therapies, Inc. (“ITI” or the “Company”) (NASDAQ:ITCI) into
potential breaches of fiduciary duty by the Company’s Board of
Directors (the “Board”).
ITI, headquartered in New York, NY, is a biopharmaceutical
company focused on the discovery and clinical development of drugs
concerning neuropsychiatric and neurological disorders. Newman
Ferrara’s investigation focuses on decisions made by the Board,
without shareholder approval, the result of which significantly
diminish shareholder value and do not benefit the Company.
Considering the Company’s lackluster performance since its 2014
initial public offering, it is clear that the Board lacks the
ability to fairly assess and oversee the Company’s direction and
leadership.
Current ITI stockholders seeking more information on this matter
are invited to contact Newman Ferrara attorneys Jeffrey Norton
(jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com) to
discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170516006492/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024